| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q34064486 | Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer |
| Q42363929 | CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy. |
| Q57123979 | Computational delineation and quantitative heterogeneity analysis of lung tumor on 18F-FDG PET for radiation dose-escalation |
| Q49594040 | Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control |
| Q50331322 | Evaluation of response after SBRT for liver tumors |
| Q52716524 | Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: Predictors from a 10-year single institution experience. |
| Q35663626 | Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non-small cell lung cancer: Evaluation of mass-like fibrosis |
| Q42686718 | Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy |
| Q64099332 | Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy |
| Q33733807 | Misjudgement of gefitinib efficacy in patients with central non-small-cell lung cancer due to obstructive atelectasis caused by stereotactic radiotherapy |
| Q37670432 | New techniques for assessing response after hypofractionated radiotherapy for lung cancer |
| Q37176293 | Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT. |
| Q35200427 | Post-therapeutic positron emission tomography/computed tomography for early detection of non-small cell lung cancer recurrence |
| Q38849150 | Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply? |
| Q64326926 | Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer |